Revvity
Jen-Chieh (James) Tseng is a Principal R&D Scientist at Revvity since May 2023, specializing in preclinical multimodal imaging for research animals. Prior to this role, Tseng served as a Principal Scientist at PerkinElmer, Inc. from January 2016 to May 2023, where responsibilities included preclinical multimodality imaging, having previously held the position of Senior PET/CT Imaging Scientist. An Associate Investigator at China Medical University in late 2015, Tseng established small animal imaging capabilities and supported intramural research. Earlier experience includes roles as an In Vivo Scientist at PerkinElmer and Imaging Biologist/Instructor at Dana-Farber Cancer Institute/Harvard Medical School. Tseng completed a Ph.D. in Cell Biology at NYU School of Medicine (2000-2005), an M.S. in Biology at New York University (1998-2000), and a Bachelor's degree in Agricultural Chemistry at National Taiwan University (1993-1997).
This person is not in any teams
This person is not in any offices
Revvity
9 followers
At Revvity, “impossible” is inspiration, and ""can't be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Learn more at www.revvity.com